SCHEMBL29664499

SCHEMBL29664499

NC(=O)c1ccccoc2cccnc2n1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.42
PKM P14618 1/20 0.42
KDM4E B2RXH2 3/20 0.40
MEN1 O00255 1/20 0.40
LMNA P02545 1/20 0.40
KMT2A Q03164 1/20 0.40
ALDH1A1 P00352 2/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
POLB P06746 1/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39
HSD17B10 Q99714 1/20 0.39
DAGLA Q9Y4D2 9/20 0.39
FAAH O00519 10/20 0.38
CES1 P23141 5/20 0.36
PARP1 P09874 1/20 0.36
CES2 O00748 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29664484 0.87 KDM4E (0.55) SMN1; SMN2PKMKDM4EMEN1LMNA
SCHEMBL566150 0.73 KDM4E (0.71) SMN1; SMN2KDM4EMEN1LMNAKMT2A
SCHEMBL30576393 0.73 KDM4E (0.71) SMN1; SMN2KDM4EMEN1LMNAKMT2A
SCHEMBL29664645 0.71 NPC1 (0.36) SMN1; SMN2KDM4EMEN1LMNAKMT2A
Hydrochloric Acid SCHEMBL27739682 0.71 KDM4E (0.69) SMN1; SMN2KDM4EMEN1LMNAKMT2A
SCHEMBL31344797 0.71 PIM1 (0.38) SMN1; SMN2KDM4EMEN1LMNAKMT2A
SCHEMBL29664625 0.70 KDM4E (0.37) SMN1; SMN2KDM4EMEN1KMT2AALDH1A1
SCHEMBL61183 0.67
SCHEMBL1505348 0.67
SCHEMBL4914089 0.67 CES2 (0.67) PKMKDM4ELMNAKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240238296-A1 METHODS OF REGULATING BCL11A EXPRESSION AND TREATMENT OF BCL11A-MEDIATED DISORDERS FULCRUM THERAPEUTICS INC (US) 2024-07-18 US disclosed
US-11590111-B2 Macrocyclic azolopyridine derivatives as EED and PRC2 modulators Fulcrum Therapeutics, Inc. (US) 2023-02-28 US disclosed
US-20220160686-A1 MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS Fulcrum Therapeutics, Inc. 2022-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240238296-A1 METHODS OF REGULATING BCL11A EXPRESSION AND TREATMENT OF BCL11A-MEDIATED DISORDERS BCLAF1, EED, BCL3 SMN1; SMN2 1053/4885PKM 3981/4885KDM4E 410/4885
US-20220160686-A1 MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS EED, EZH2, BMI1 SMN1; SMN2 676/4885PKM 1415/4885KDM4E 88/4885
US-11590111-B2 Macrocyclic azolopyridine derivatives as EED and PRC2 modulators EED, EZH2, BMI1 SMN1; SMN2 676/4885PKM 1415/4885KDM4E 88/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.